<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Resistance of &lt;i&gt;Streptococcus pneumoniae&lt;/i&gt; to beta-lactam antibiotics
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Resistance of
       <i>
        Streptococcus pneumoniae
       </i>
       to beta-lactam antibiotics
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Resistance of
        <i>
         Streptococcus pneumoniae
        </i>
        to beta-lactam antibiotics
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel M Musher, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas M File, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         From the beginning of the antibiotic era to the mid-1970s,
         <em>
          Streptococcus pneumoniae
         </em>
         (pneumococcus) remained uniformly susceptible to all classes of antibiotics that had been active against this organism, with the possible exception of
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         . Thus, the medical profession had a rude awakening in 1977 and 1978 when outbreaks of infection due to antibiotic-resistant pneumococci occurred in Durban and Johannesburg, South Africa [
         <a href="#rid1">
          1,2
         </a>
         ]. These outbreaks originated in infectious diseases hospitals where children with serious viral infections were routinely treated "prophylactically" with antibiotics. Although originally called penicillin-resistant pneumococci (PRP), these bacteria appeared to have acquired genetic material that encoded resistance to penicillin as well as to other commonly used antibiotics.
        </p>
        <p>
         In the ensuing decades, resistance of pneumococci to a variety of antimicrobial agents has evolved from an ominous medical curiosity to a worldwide health problem. Pneumococcal resistance has increased to a point that it is clinically relevant in the following classes of antibiotics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beta-lactams (penicillins, cephalosporins, and carbapenems)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrolides (
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lincosamides (
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tetracyclines
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhibitors of folate synthesis (
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         [TMP-SMX])
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fluoroquinolones (
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8760" href="/z/d/drug information/8760.html" rel="external">
          gemifloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         A number of studies have addressed apparent risk factors for the acquisition of antibiotic-resistant pneumococcal strains [
         <a href="#rid3">
          3-6
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous antibiotic use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous time spent in daycare (for children) or in an institutional setting, including nursing home, long-term care facility, or a shelter for people who are homeless (for adults)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recent respiratory infections
        </p>
        <p>
        </p>
        <p>
         The mechanisms of action and resistance, definitions of resistance in relation to clinically achievable drug concentrations, and clinical data on the outcome of therapy in otitis, sinusitis, acute exacerbations of chronic bronchitis, pneumonia, meningitis, and bacteremia will be reviewed here for the beta-lactams. Resistance to the other classes of drugs is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7028.html" rel="external">
          "Resistance of
          <i>
           Streptococcus pneumoniae
          </i>
          to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7033.html" rel="external">
          "Resistance of
          <i>
           Streptococcus pneumoniae
          </i>
          to the macrolides, azalides, and lincosamides"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          MECHANISM OF ACTION AND RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Beta-lactam antibiotics inhibit pneumococcal growth by irreversibly binding the active site of enzymes that are needed to synthesize peptidoglycan, the major constituent of the cell wall. When penicillin-susceptible pneumococci are incubated with low concentrations of radiolabeled penicillin and then subjected to protein electrophoresis and radioautography, five distinct bands, each representing a different enzyme that contributes to cell wall synthesis, are detected. These enzymes are often called "penicillin-binding proteins." In strains that have reduced susceptibility to penicillin, the affinity of the antibiotic for one or more of these enzymes is reduced; incubation with low concentrations of penicillin, followed by radioautography, detects reduced or absent labeling of one or more of the five bands (
         <a class="graphic graphic_figure graphicRef75661" href="/z/d/graphic/75661.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. However, labeling can generally be restored at higher antibiotic concentrations.
        </p>
        <p>
         These observations explain the central clinical teaching that, in treating infections that do not involve the central nervous system (CNS), decreased susceptibility of pneumococci to penicillins is usually overcome with penicillin doses that are generally prescribed. The same principle applies to cephalosporins and carbapenems. However, there are differences in the capacity of these drugs to overcome the resistance, and clinicians need to know where each falls in the spectrum of efficacy at increased concentrations (
         <a class="graphic graphic_table graphicRef76028" href="/z/d/graphic/76028.html" rel="external">
          table 1
         </a>
         ). Whether in vitro resistance to macrolides (depending upon the molecular basis for the resistance) or the fluoroquinolones can be overcome by increased doses of drug is controversial. Resistance to folate inhibitors or tetracyclines cannot be overcome by increasing the antibiotic dose. (See
         <a class="medical medical_review" href="/z/d/html/7033.html" rel="external">
          "Resistance of
          <i>
           Streptococcus pneumoniae
          </i>
          to the macrolides, azalides, and lincosamides"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7028.html" rel="external">
          "Resistance of
          <i>
           Streptococcus pneumoniae
          </i>
          to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Definitions and prevalence of resistance
         </span>
         <span class="headingEndMark">
          —
         </span>
         The definitions of susceptibility have been changed and can be confusing (
         <a class="graphic graphic_table graphicRef63881" href="/z/d/graphic/63881.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid8">
          8,9
         </a>
         ]. Depending upon the parenteral dose being administered, penicillin levels in plasma and, therefore, in alveoli, soft tissues, sinuses, and perhaps the middle ear tend to exceed 2 mcg/mL for most of the treatment period. The peak levels attained with oral dosage are, of course, much lower, but
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         has a much longer half-life, and 500 mg every six hours orally maintains levels above 2 mcg/mL for most of the treatment period. Because of the blood-brain barrier, cerebrospinal fluid (CSF) levels in children who are receiving 250,000 units/kg per day in six divided doses generally do not exceed 1 to 2 mcg/mL [
         <a href="#rid10">
          10,11
         </a>
         ]. Thus, currently accepted definitions of resistance consider the site of the infection, the route of administration of the antibiotic, and the dosage, as discussed in the following section.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Penicillin
         </span>
         <span class="headingEndMark">
          —
         </span>
         For non-CNS infections, when an infection is being treated with intravenous (IV) antibiotics, the following definitions for penicillin resistance apply:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Susceptible – Minimum inhibitory concentration (MIC) ≤2 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate – MIC &gt;2 and ≤4 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resistant – MIC &gt;4 mcg/mL
        </p>
        <p>
        </p>
        <p>
         When oral penicillin is being used, the following definitions apply:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Susceptible – MIC ≤0.06 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate – MIC &gt;0.06 and ≤1 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resistant – MIC &gt;1 mcg/mL
        </p>
        <p>
        </p>
        <p>
         For CNS infections, the following definitions apply:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Susceptible – MIC ≤0.06 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resistant – MIC &gt;0.06 mcg/mL
        </p>
        <p>
        </p>
        <p>
         There is no intermediate category for CNS infections.
        </p>
        <p>
         Resistance rates vary regionally:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the early 2000s, using older definitions of resistance, approximately 60 percent of pneumococci in the United States were said to be susceptible to penicillin, 20 percent intermediately resistant, and 20 percent resistant [
         <a href="#rid12">
          12,13
         </a>
         ]. Using current definitions, rates of resistance are much lower. At present, when usual doses of parenteral penicillin are used to treat pneumococcal infection that does not involve the CNS, 96 percent of isolates are susceptible, 2 percent are intermediate, and 2 percent are resistant [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Higher rates of penicillin resistance have been described in other countries. For example, among 685
         <em>
          S. pneumoniae
         </em>
         isolates from 14 centers in 11 Asian countries that were collected from January 2000 to June 2001 [
         <a href="#rid15">
          15
         </a>
         ], 52 percent were reported as not susceptible to penicillin, with rates of resistance as high as 74 percent in Vietnam. However, using definitions of susceptibility, resistance rates are quite similar to those in the United States [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Despite the improved rates of penicillin susceptibility reported for pneumococcal isolates in the United States, it is important to note that rates of penicillin susceptibility may fluctuate, largely related to the effects of widespread use of the pneumococcal conjugate vaccine and local habits of antibiotic prescribing. In Spain, for example, emergence of strains with reduced susceptibility to penicillin has been attributed to increased uptake of
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          PCV13
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H54044453">
         <span class="h4">
          Impact of the pneumococcal conjugate vaccine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of pneumococcal conjugate vaccines in children reduces carriage of vaccine strains and therefore reduces the spread of these strains to adults. Many of the strains included in the original 7-valent conjugate vaccine had reduced susceptibility to penicillin. In the United States, widespread use of PCV7, a protein conjugate pneumococcal vaccine that contains polysaccharides from seven serotypes that commonly colonized and infected young children, was followed by a &gt;90 percent reduction in invasive disease caused by vaccine serotypes in both children and adults and, therefore, by a reduction in the overall rate of nonsusceptibility [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         As a result of widespread vaccination of children with conjugate pneumococcal vaccine, most vaccine strains have largely disappeared, and new strains have emerged (called "replacement strains") [
         <a href="#rid19">
          19
         </a>
         ]. On the one hand, those that were targeted by the vaccine and have largely disappeared tended to be resistant ones carried by toddlers and young children. On the other hand, some of the replacement strains have been resistant to penicillin and other antibiotics. Serotype 19A emerged so promptly after introduction of 7-valent pneumococcal vaccine that it was added to the 13-valent vaccine. Since the introduction of the
         <a class="drug drug_general" data-topicid="9906" href="/z/d/drug information/9906.html" rel="external">
          13-valent pneumococcal conjugate vaccine
         </a>
         (PCV13) in 2010, other emerging serotypes that are not contained in either PCV13 or the
         <a class="drug drug_general" data-topicid="9784" href="/z/d/drug information/9784.html" rel="external">
          pneumococcal polysaccharide vaccine
         </a>
         (PPSV23) and that exhibit a substantial degree of antimicrobial resistance have been reported; examples of these serotypes include serotypes 15B, 23A, 23B, and 35B [
         <a href="#rid20">
          20,21
         </a>
         ].
         <a class="drug drug_general" data-topicid="131831" href="/z/d/drug information/131831.html" rel="external">
          PCV20
         </a>
         is now available, and will cover serotype 15B, but new capsular types will continue to emerge.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Amoxicillin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most clinicians prescribe
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         instead of penicillin because of its more reliable absorption from the gastrointestinal tract and longer half-life. These pharmacologic considerations help to explain the discrepancies between definitions of susceptibility to penicillin and amoxicillin (
         <a class="graphic graphic_table graphicRef63881" href="/z/d/graphic/63881.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Cephalosporins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar concepts that are operative in the mechanisms for penicillin resistance apply to the cephalosporins [
         <a href="#rid12">
          12
         </a>
         ]. With
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         , for example, 50 mg/kg given intravenously yields peak serum levels of 250 mcg/mL and peak CSF levels of 2 to 5 mcg/mL (
         <a class="graphic graphic_figure graphicRef66474" href="/z/d/graphic/66474.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid22">
          22
         </a>
         ]. The drug declines in the bloodstream with a half-life of six hours. Clearly, treatment of non-CNS infections in adults with 1 g ceftriaxone given every 24 hours (approximately 12.5 mg/kg) should be effective against all but the most highly resistant isolates. Virtually all pneumococcal isolates reported are highly susceptible to
         <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">
          ceftaroline
         </a>
         [
         <a href="#rid23">
          23,24
         </a>
         ].
        </p>
        <p>
         Definitions of susceptibility to
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         for non-CNS isolates of
         <em>
          S. pneumoniae
         </em>
         are as follows [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Susceptible – MIC ≤1 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate – MIC &gt;1 and ≤2 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resistant – MIC &gt;2 mcg/mL
        </p>
        <p>
        </p>
        <p>
         According to these definitions, in the United States, 96.6 percent of pneumococci are susceptible, 2.8 percent are intermediate, and 0.6 percent are resistant to
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         and
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         [
         <a href="#rid25">
          25
         </a>
         ].
         <a class="drug drug_general" data-topicid="16088" href="/z/d/drug information/16088.html" rel="external">
          Ceftaroline
         </a>
         , a newer cephalosporin, appears to be particularly effective in vitro against pneumococcal isolates [
         <a href="#rid24">
          24
         </a>
         ]. The reader should conclude that nonmeningeal infections caused by pneumococcus are very likely to respond to currently used doses of ceftriaxone, cefotaxime,
         <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">
          cefepime
         </a>
         , or ceftaroline. The same applies to
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         or
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         . Even in Asia, only 3 percent of pneumococcal isolates are resistant to ceftriaxone [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Current definitions of susceptibility for CNS isolates of
         <em>
          S. pneumoniae
         </em>
         to
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Susceptible – MIC ≤0.5 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermediate – MIC &gt;0.5 and ≤1 mcg/mL
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resistant – MIC &gt;1 mcg/mL
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H132687408">
         <span class="h3">
          Carbapenems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resistance to carbapenems, including
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         , appears to parallel that of third-generation cephalosporins, based upon rising MICs in the United States [
         <a href="#rid26">
          26
         </a>
         ] and reports from countries such as Italy [
         <a href="#rid23">
          23
         </a>
         ] and Japan [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          RESISTANCE AND THE OUTCOME OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Resistance of pneumococci to beta-lactam antibiotics is relative and, in the treatment of pneumonia, can generally be overcome by the doses currently in use. In cases other than meningitis, approximately 95 percent of pneumococcal infections will respond to treatment with standard-doses of beta-lactam antibiotics (eg, 1 gram of
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         daily for an average adult). However, in treating meningitis, one needs to pay particular attention to the measured susceptibility of the infecting organism.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Otitis media
         </span>
         <span class="headingEndMark">
          —
         </span>
         After young children with otitis receive 30 mg/kg of
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         orally, mean concentrations in the middle ear fluid are approximately 4 to 7 mcg/mL [
         <a href="#rid28">
          28,29
         </a>
         ]. Meticulous studies have shown that the outcome of amoxicillin treatment for pneumococcal otitis media correlates well with the amoxicillin susceptibility of the infecting organism [
         <a href="#rid30">
          30
         </a>
         ]. These data validate the current recommendations to administer 80 to 90 mg/kg per day of amoxicillin orally in two divided doses, which is effective for all but the most resistant pneumococci [
         <a href="#rid31">
          31,32
         </a>
         ]. In contrast, a drug such as
         <a class="drug drug_general" data-topicid="9211" href="/z/d/drug information/9211.html" rel="external">
          cefaclor
         </a>
         (
         <a class="graphic graphic_table graphicRef76028" href="/z/d/graphic/76028.html" rel="external">
          table 1
         </a>
         ), which has a high MIC for penicillin-resistant pneumococci relative to achievable serum levels, is much less likely to produce a cure [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5959.html" rel="external">
          "Acute otitis media in children: Treatment", section on 'Initial antibiotic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Acute purulent rhinosinusitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar data are not available to relate the outcome of treatment for acute purulent rhinosinusitis to antibiotic resistance. Nevertheless, it seems likely that the same considerations would apply as for otitis media. Rhinosinusitis responds very well to treatment with
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         [
         <a href="#rid34">
          34
         </a>
         ] and recommendations for treating rhinosinusitis are nearly identical to those for otitis. The increasing prevalence of beta-lactamase-producing
         <em>
          Haemophilus influenzae
         </em>
         in the United States has led to a preference for amoxicillin-clavulanic acid in treating these upper respiratory conditions. (See
         <a class="medical medical_review" href="/z/d/html/83012.html" rel="external">
          "Uncomplicated acute sinusitis and rhinosinusitis in adults: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Pneumonia and bacteremia
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the preantibiotic era, pneumococci caused 85 to 95 percent of all community-acquired pneumonia (CAP). Studies in the United States have implicated
         <em>
          S. pneumoniae
         </em>
         in no more than 5 to 8 percent of CAP [
         <a href="#rid35">
          35,36
         </a>
         ]. However, one subsequent study suggests that among hospitalized patients able to provide a sputum sample at admission,
         <em>
          S. pneumoniae
         </em>
         was detected alone or with a respiratory virus in 20 percent of cases and together with a bacterial infection in an additional 5 percent [
         <a href="#rid37">
          37
         </a>
         ]. In Europe, pneumococcus almost certainly causes a higher proportion of CAP [
         <a href="#rid38">
          38-40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">
          "Treatment of community-acquired pneumonia in adults in the outpatient setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         .)
        </p>
        <p>
         In summary, at present, nearly all pneumococcal infections other than those involving the central nervous system appear to respond to currently recommended doses of beta-lactam antibiotics.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Meningitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Because of the limited ability of beta-lactams to cross the blood-brain barrier, only about 80 percent of pneumococcus isolates are fully susceptible at achievable concentrations. There is substantial risk that meningitis caused by pneumococci that are not fully susceptible to beta-lactam antibiotics will not respond to treatment with these drugs [
         <a href="#rid41">
          41
         </a>
         ]. For example, meningitis caused by strains with a
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         MIC &gt;2 mcg/mL are likely to fail to respond to treatment with recommended doses of this drug [
         <a href="#rid42">
          42
         </a>
         ], whereas those with MIC = 1 mcg/mL may or may not respond (
         <a class="graphic graphic_table graphicRef63881" href="/z/d/graphic/63881.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid42">
          42-44
         </a>
         ].
        </p>
        <p>
         These findings justify the recommendation that initial empiric therapy of pneumococcal meningitis be with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         in addition to
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         or
         <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">
          cefotaxime
         </a>
         [
         <a href="#rid41">
          41,45
         </a>
         ], until the results of susceptibility testing are known. When susceptibility studies are completed, vancomycin can be discontinued if the infecting organism is susceptible to beta-lactam antibiotics. However, if the organism is intermediate or resistant, vancomycin should be continued for the entire treatment period. (See
         <a class="medical medical_review" href="/z/d/html/1283.html" rel="external">
          "Treatment of bacterial meningitis caused by specific pathogens in adults", section on 'Streptococcus pneumoniae'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Streptococcus pneumoniae'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanisms of resistance
         </strong>
         – Early in the antibiotic era, pneumococci were uniformly susceptible to penicillin. Resistance to penicillin and other beta-lactams arose when mutations appeared in enzymes that are needed to synthesize the cell wall, the active site at which beta-lactams block the replication of pneumococci. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Mechanism of action and resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose-dependent nonsusceptibility
         </strong>
         – Nonsusceptibility of pneumococci to beta-lactam resistance antibiotics is dose dependent; when non-central nervous system (CNS) infections are being treated, it can be overcome by the doses of beta-lactams in use. In cases other than meningitis, approximately 95 percent of pneumococcal infections will respond to treatment with beta-lactams. (See
         <a class="local">
          'Resistance and the outcome of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Limited penetration of beta-lactams to CNS
         </strong>
         – Because of the limited ability of beta-lactams to cross the blood-brain barrier, only about 80 percent of pneumococcus isolates are fully susceptible at concentrations achievable in the CNS. Therefore, resistance is of much greater consequence in cases of meningitis than in cases of disease outside the CNS. (See
         <a class="local">
          'Meningitis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Susceptibility thresholds vary by site of infection
         </strong>
         – Accordingly, microbiology laboratories report pneumococcal susceptibility to beta-lactams based on the site of infection, distinguishing between isolates that cause meningitis and those that cause infections at other sites (
         <a class="graphic graphic_table graphicRef63881" href="/z/d/graphic/63881.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Meningitis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Appelbaum PC, Bhamjee A, Scragg JN, et al. Streptococcus pneumoniae resistant to penicillin and chloramphenicol. Lancet 1977; 2:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bédos JP, Chevret S, Chastang C, et al. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis 1996; 22:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno F, Crisp C, Jorgensen JH, Patterson JE. The clinical and molecular epidemiology of bacteremias at a university hospital caused by pneumococci not susceptible to penicillin. J Infect Dis 1995; 172:427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruhe JJ, Myers L, Mushatt D, Hasbun R. High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup. Clin Infect Dis 2004; 38:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40:1288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markiewicz Z, Tomasz A. Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci. J Clin Microbiol 1989; 27:405.
          </a>
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed. CLSI Supplement M100. Clinical and Laboratory Standards Institute 2022, p.94.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis 2009; 48:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hieber JP, Nelson JD. A pharmacologic evaluation of penicillin in children with purulent meningitis. N Engl J Med 1977; 297:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Bartlett JG, Doern GV. A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics. Arch Intern Med 2001; 161:2538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thornsberry C, Sahm DF, Kelly LJ, et al. Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002; 34 Suppl 1:S4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whitney CG, Farley MM, Hadler J, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000; 343:1917.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. 2019. Active Bacterial Core Surveillance Report, Emerging
Infections Program Network, Streptococcus pneumoniae, 2019. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf (Accessed on February 04, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Song JH, Jung SI, Ko KS, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004; 48:2101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim SH, Song JH, Chung DR, et al. Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Antimicrob Agents Chemother 2012; 56:1418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sempere J, Llamosí M, López Ruiz B, et al. Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study. Lancet Microbe 2022; 3:e744.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pick H, Daniel P, Rodrigo C, et al. Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18. Thorax 2020; 75:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olarte L, Barson WJ, Barson RM, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children. Clin Infect Dis 2015; 61:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richter SS, Diekema DJ, Heilmann KP, et al. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrob Agents Chemother 2014; 58:6484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Rio M, McCracken GH Jr, Nelson JD, et al. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother 1982; 22:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marchese A, Gualco L, Schito AM, et al. In vitro activity of ertapenem against selected respiratory pathogens. J Antimicrob Chemother 2004; 54:944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacobs MR, Good CE, Windau AR, et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010; 54:2716.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae, 2014. http://www.cdc.gov/abcs/reports-findings/survreports/spneu14.html (Accessed on December 05, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaur R, Pham M, Yu KOA, Pichichero ME. Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting. Clin Infect Dis 2021; 72:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakano S, Fujisawa T, Ito Y, et al. Penicillin-Binding Protein Typing, Antibiotic Resistance Gene Identification, and Molecular Phylogenetic Analysis of Meropenem-Resistant Streptococcus pneumoniae Serotype 19A-CC3111 Strains in Japan. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison CJ, Welch DF. Middle ear effusion amoxicillin concentrations in acute otitis media. Pediatr Infect Dis J 1998; 17:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seikel K, Shelton S, McCracken GH Jr. Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media. Pediatr Infect Dis J 1998; 17:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramakrishnan K, Sparks RA, Berryhill WE. Diagnosis and treatment of otitis media. Am Fam Physician 2007; 76:1650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. Pediatrics 2013; 131:e964.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan R, Leibovitz E, Fliss DM, et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams JW Jr, Aguilar C, Makela M, et al. Antibiotics for acute maxillary sinusitis. Cochrane Database Syst Rev 2000; :CD000243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013; 67:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Musher DM, Jesudasen SS, Barwatt JW, et al. Normal Respiratory Flora as a Cause of Community-Acquired Pneumonia. Open Forum Infect Dis 2020; 7:ofaa307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bjarnason A, Westin J, Lindh M, et al. Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study. Open Forum Infect Dis 2018; 5:ofy010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ceccato A, Cilloniz C, Martin-Loeches I, et al. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. Chest 2019; 155:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SL. Management of pneumococcal meningitis. Pediatr Infect Dis J 2002; 21:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SL, Mason EO Jr. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev 1998; 11:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan TQ, Schutze GE, Mason EO Jr, Kaplan SL. Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1994; 38:918.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiore AE, Moroney JF, Farley MM, et al. Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance. Clin Infect Dis 2000; 30:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004; 39:1267.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7034 Version 30.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/72950" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Streptococcus pneumoniae resistant to penicillin and chloramphenicol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29219" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Emergence of multiply resistant pneumococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8824968" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7622885" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The clinical and molecular epidemiology of bacteremias at a university hospital caused by pneumococci not susceptible to penicillin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14765343" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : High-level penicillin-nonsusceptible Streptococcus pneumoniae bacteremia: identification of a low-risk subgroup.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15825031" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Predicting antimicrobial resistance in invasive pneumococcal infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2715316" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2715316" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Variation in penicillin-binding protein patterns of penicillin-resistant clinical isolates of pneumococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19400744" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/882110" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A pharmacologic evaluation of penicillin in children with purulent meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11718584" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A fresh look at the definition of susceptibility of Streptococcus pneumoniae to beta-lactam antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11810606" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136262" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11136262" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15155207" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22232285" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Changing trends in antimicrobial resistance and serotypes of Streptococcus pneumoniae isolates in Asian countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35932764" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004-20: a national surveillance study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19947881" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31594801" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Pneumococcal serotype trends, surveillance and risk factors in UK adult pneumonia, 2013-18.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25972022" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25136018" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6295262" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15472001" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : In vitro activity of ertapenem against selected respiratory pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308374" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308374" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32067037" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Rising Pneumococcal Antibiotic Resistance in the Post-13-Valent Pneumococcal Conjugate Vaccine Era in Pediatric Isolates From a Primary Care Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31235623" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Penicillin-Binding Protein Typing, Antibiotic Resistance Gene Identification, and Molecular Phylogenetic Analysis of Meropenem-Resistant Streptococcus pneumoniae Serotype 19A-CC3111 Strains in Japan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9686739" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Middle ear effusion amoxicillin concentrations in acute otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9802655" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Middle ear fluid concentrations of amoxicillin after large dosages in children with acute otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10693993" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18092706" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Diagnosis and treatment of otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23439909" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The diagnosis and management of acute otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10602721" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10796515" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Antibiotics for acute maxillary sinusitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23523447" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32968689" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Normal Respiratory Flora as a Cause of Community-Acquired Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25785969" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29479548" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30471269" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Effect of Combinedβ-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12182395" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Management of pneumococcal meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9767060" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Management of infections due to antibiotic-resistant Streptococcus pneumoniae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067771" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Antibiotic therapy and acute outcome of meningitis due to Streptococcus pneumoniae considered intermediately susceptible to broad-spectrum cephalosporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10619736" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Clinical outcomes of meningitis caused by Streptococcus pneumoniae in the era of antibiotic resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494903" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Practice guidelines for the management of bacterial meningitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
